Magnus Blixt to become CEO of Dignitana AB

The Board of Directors of Dignitana AB has appointed Magnus Blixt as the new CEO of Dignitana. He will assume CEO responsibilities after the Annual General Meeting on 25 May 2022.  At that time current CEO William Cronin will transition to serve as Deputy Chairman of the Board of Directors and will be a Senior Advisor to the company regarding US market and reimbursement strategies.

Files for download
Dignitana Release - wkr0006.pdf



Magnus Blixt is currently CFO of CellaVision AB, a global medical technology company listed on the Nasdaq Nordic Mid Cap list. Blixt has held that role since 2013 and has supported a profitable growth agenda generated by a scalable indirect business model. He has extensive experience developing small and medium-sized companies focusing on business performance and process improvements. He previously held positions in the SKF Group as Business Demand Manager and Operations Manager, and as CFO of an SKF Sealing Solutions company in the United States he supported the integration of that company into the broader SKF organization. He has an MBA from Lund University.


“I appreciate the entrepreneurial spirit of Dignitana and I see many similarities in this company compared to where CellaVision was when I joined that company,” said Magnus Blixt. “Dignitana is a growing company with tremendous potential – it has global reach, an excellent product, and a solid foundation. I am excited about the opportunity and look forward to continuing the good work of the company to improve well-being and the lives of cancer patients.”


“The strategic expansion of the company is our top priority,” said Klas Arildsson, Chairman of the Board, Dignitana AB. “We are well-positioned to take advantage of the opportunities before us in the critical US market and around the globe, and the financial and operational experience that Magnus Blixt brings will be a tremendous asset to the Company.”


To support Dignitana’s commitment to global expansion the CEO position will be based at the Company headquarters in Lund along with other key positions.

For More Information Contact 

Klas Arildsson, Chairman of the Board of Directors,

Melissa Bourestom, VP Corporate Communications,  +1 469-518-5031

About Dignitana

Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001.  Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and operations in Dallas, Texas in the United States.  Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Certified Adviser is Redeye AB +46 8 121 576 90, Learn more at or